HER2-positive breast cancer Clinical Trials

Recruiting her2-positive breast cancer studies with sites across the US, sourced from ClinicalTrials.gov and refreshed daily. Free to join — find one near you below.

Clinical trials study new ways to prevent, detect, or treat her2-positive breast cancer. Joining one can give you access to investigational treatments and close monitoring by a specialist research team — at no cost — while helping advance care for others. Below are recruiting her2-positive breast cancer studies with sites across the US; use the location tools to find ones near you.

What to expect

Screening first. The study team reviews your eligibility before anything else — there's no obligation to continue.
Informed consent. You'll get a full explanation of the study, its potential risks and benefits, and can withdraw at any time.
No cost to you. Study visits, tests, and the investigational treatment are covered; many studies reimburse travel.

Recruiting her2-positive breast cancer trials

Within

Fulvestaciclib Combined With Anti-HER2 and Endocrine Therapy for HR+/HER2+ Advanced Breast Cancer

for Breast Cancer

Sponsor: Fudan University

Sex: All·Age: 18+

Code: NCT07716046·Phase 2

Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer

for Breast Cancer

1 site in Columbus

Sponsor: Ohio State University Comprehensive Cancer Center

Sex: All·Age: 18+

Code: NCT07217990·Phase 1, Phase 2

HER2 Vaccine for Locally Advanced Breast Cancer

for Breast Cancer

1 site in Indianapolis

Sponsor: Pravin T.P Kaumaya

Sex: All·Age: 18+

Code: NCT06949410·Phase 1

Apply to this trial

Trastuzumab Deruxtecan + Stereotactic Radiosurgery (SRS) in HER2+ Breast Cancer Brain Metastases

for Breast Cancer

1 site in Miami

Sponsor: Baptist Health South Florida

Sex: Female·Age: 18+

Code: NCT07454668·Phase 1

Pilot Study on the Clinical Efficacy of Focused Ultrasound-Mediated Targeted Drug Delivery System Combined With Neoadjuvant Therapy for HER2-Positive Breast Cancer

for HER2-positive Breast Cancer

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

Sex: Female·Age: 18 - 70

Code: NCT07616440

Apply to this trial

Trastuzumab Rezetecan (T-DXh) in HER2+ Breast Cancer With Non-pCR After TCbHP

for Breast Cancer

Sponsor: The First Affiliated Hospital with Nanjing Medical University

Sex: Female·Age: 18+

Code: NCT07589699·Phase 4

RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

for HER2-positive Breast Cancer

Sponsor: Hoffmann-La Roche

Sex: All·Age: 18+

Code: NCT07413939·Phase 2, Phase 3

Apply to this trial

Platform Trial Assessing Uptake, Safety and Efficacy of Theranostic Agents in Solid Tumors With Active Brain Metastases

for Solid Tumors

Sponsor: MedSIR

Sex: All·Age: 18+

Code: NCT07178938·Phase 2

A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer

for HER2-positive Breast Cancer

Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.

Sex: Female·Age: 18 - 75

Code: NCT07518173·Phase 3

Apply to this trial

SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized Study

for Breast Cancer

Sponsor: Peking University Cancer Hospital & Institute

Sex: All·Age: 18+

Code: NCT07417241·Phase 2

Pyrotinib Combined With Trastuzumab and Pertuzumab for Maintenance Therapy in HER2-Positive Advanced Breast Cancer

for HER2-positive Breast Cancer

Sponsor: Peking University Cancer Hospital & Institute

Sex: All·Age: 18+

Code: NCT07470203

Trastuzumab Rezetecan Neoadjuvant Therapy in THP-Insensitive HER2-Positive Early Breast Cancer

for HER2-positive Breast Cancer

Sponsor: The First Affiliated Hospital of Soochow University

Sex: Female·Age: 18+

Code: NCT07647263·Phase 2

Apply to this trial

HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission

for Breast Cancer

7 sites incl. Basking Ridge

Sponsor: Memorial Sloan Kettering Cancer Center

Sex: All·Age: 18+

Code: NCT07459673·Phase 2

Apply to this trial

IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer

for HER2-positive Breast Cancer

Sponsor: Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.

Sex: All·Age: 18+

Code: NCT07377643·Phase 3

Apply to this trial

Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)

for Breast Cancer (Locally Advanced or Metastatic)

Sponsor: Beijing Biotech

Sex: All·Age: 18 - 75

Code: NCT07486089·Phase 1, Phase 2

Apply to this trial

Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC

for Breast Cancer (Advanced/Metastatic)

Sponsor: Beijing Biotech

Sex: All·Age: 18 - 75

Code: NCT07510802·Phase 1, Phase 2

Apply to this trial

RC48 Combined With Chemotherapy in HER2-Positive Advanced Breast Cancer Patients With Prior TOP1i-ADC Failure

for HER2-positive Breast Cancer

Sponsor: Fudan University

Sex: Female·Age: 18+

Code: NCT07366840·Phase 2, Phase 3

A Study to Assess the Efficiency of Trastuzumab Deruxtecan in Russian Breast Cancer Patients

for HER2-positive Breast Cancer

Sponsor: Blokhin's Russian Cancer Research Center

Sex: All·Age: 18 - 80

Code: NCT07281001

Apply to this trial

T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain Metastasis

for Breast Cancer With Brain Metastasis

Sponsor: Fudan University

Sex: Female·Age: 18 - 70

Code: NCT07152782·Phase 2

Primary Prevention of Thrombocytopenia Associated With T-DM1 Therapy in HER2 Positive Breast Cancer With Herombopag

for HER2-positive Breast Cancer

Sponsor: Zhenzhen Liu

Sex: All·Age: 18+

Code: NCT07198672

A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

for HER2-positive Breast Cancer

22 sites incl. Long Beach

Sponsor: Jazz Pharmaceuticals

Sex: All·Age: 18+

Code: NCT07102381·Phase 2

Apply to this trial

A Study of Surgery and Radiotherapy in People With Breast Cancer

for Metastatic Breast Cancer

7 sites incl. Basking Ridge

Sponsor: Memorial Sloan Kettering Cancer Center

Sex: All·Age: 18+

Code: NCT07053085·Phase 2

Apply to this trial

A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer

for HER2-positive Breast Cancer

Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Sex: All·Age: 18 - 75

Code: NCT07043725·Phase 3

Apply to this trial

HB1801 Combined Treatment of HER2-positive Breast Cancer

for HER2-positive Breast Cancer

Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Sex: All·Age: 18+

Code: NCT07116824·Phase 2

Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study

for HER2-positive Breast Cancer

Sponsor: Fudan University

Sex: Female·Age: 18+

Code: NCT07179939·Phase 2

This Study Aims to Optimize Neoadjuvant Therapy for HER2-positive Breast Cancer by Implementing a Dynamic Monitoring-guided Treatment Strategy.

for HER2-positive Breast Cancer

Sponsor: Hebei Medical University Fourth Hospital

Sex: Female·Age: 18 - 70

Code: NCT06973525·Phase 2

Probiotics for Prevention of Neratinib-Induced Diarrhea in Breast Cancer Patients

for HER2-positive Breast Cancer

Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Sex: Female·Age: 18+

Code: NCT06892093

Apply to this trial

A Randomized, Open-label, Multi-center Phase III Study Comparing the Efficacy of Oral Chemotherapy Combined With Trastuzumab Versus Paclitaxel Combined With Trastuzumab in the Adjuvant Treatment of HER2-positive, Lymph Node-negative Early Breast Cancer Patients(ORCHID-PLUS)

for HER2-positive Breast Cancer

Sponsor: Fudan University

Sex: Female·Age: 18 - 70

Code: NCT06992882·Phase 3

Apply to this trial

Neratinib in Extended Adjuvant Treatment for HER2+ Early Breast Cancer With pCR But High-Risk Features: A Hebei Multi-Center Real-World Study

for HER2-positive Breast Cancer

Sponsor: Hebei Medical University Fourth Hospital

Sex: Female·Age: 18+

Code: NCT07019272

Oral Metronomic Capecitabine Combined With Pyrotinib in ADC-treated HER2-positive Metastatic Breast Cancer

for HER2-positive Breast Cancer

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Sex: All·Age: 18 - 75

Code: NCT07019337·Phase 2

Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab Failure

for Breast Cancer

Sponsor: Tianjin Medical University Cancer Institute and Hospital

Sex: Female·Age: 18 - 75

Code: NCT07708194·Phase 1, Phase 2

Apply to this trial

A Study of BL-M07D1 With or Without Pertuzumab Versus Taxane + Trastuzumab and Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer

for HER2-positive Breast Cancer

Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.

Sex: Female·Age: 18 - 75

Code: NCT06891833·Phase 2, Phase 3

Apply to this trial

A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy

for HER2-positive Breast Cancer

Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.

Sex: Female·Age: 18 - 75

Code: NCT06830889·Phase 3

Apply to this trial

Efficacy and Safety of Trastuzumab-rezetecan in HER2-Expressing Breast Cancer

for Trastuzumab-rezetecan

Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Sex: All·Age: 18+

Code: NCT07358182

Apply to this trial

Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery

for Human Epidermal Growth Factor 2 Negative Carcinoma of Breast

Sponsor: University of Chicago

Sex: Female·Age: 18+

Code: NCT06348134·Phase 2

Apply to this trial

NearWave Optical Molecular Monitoring

for Breast Cancer

1 site in Indianapolis

Sponsor: Indiana University

Sex: Female·Age: 18+

Code: NCT06744465

Apply to this trial

Decreasing Treatment for Metastatic HER2-Positive Breast Cancer With Undectable Cancer Levels in Blood Tests.

for Metastatic Breast Cancer

Sponsor: UNICANCER

Sex: All·Age: 18+

Code: NCT06450314·Phase 2

Apply to this trial

HER-2 B Cell Peptide Vaccine

for Metastatic Breast Cancer

1 site in Indianpolis

Sponsor: Pravin T.P Kaumaya

Sex: All·Age: 18+

Code: NCT06414733·Phase 1

Apply to this trial

A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer

for HER2-positive Breast Cancer

Sponsor: GeneQuantum Healthcare (Suzhou) Co., Ltd.

Sex: All·Age: 18 - 75

Code: NCT07673029·Phase 3

Apply to this trial

Evaluation of the Cardioprotective Effect of Nebivolol on Trastuzumab-Induced Cardiotoxicity in Breast Cancer Patients

for HER2-positive Breast Cancer

Sponsor: Ain Shams University

Sex: Female·Age: 18 - 65

Code: NCT07233499·Phase 2

Apply to this trial

Pyrotinib in HER2-positive Early Breast Cancer

for HER2-positive Breast Cancer

Sponsor: Nie Jianyun

Sex: Female·Age: 18 - 75

Code: NCT06718335

Tumor-microenvironment Spatial Interaction to Identify Markers of Resistance to Therapy in HER2+ Breast Cancer Patients

for HER2-positive Breast Cancer

Sponsor: Giampaolo Bianchini

Sex: Female·Age: 18+

Code: NCT06518382

Apply to this trial

BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer

for Breast Cancer

1 site in Chicago

Sponsor: University of Illinois at Chicago

Sex: All·Age: 18+

Code: NCT06441890·Phase 2

Apply to this trial

Neoadjuvant Chemotherapy Plus Pyrotinib and Trastuzumab for HER2-positive Breast Cancer (NEOTORCH-BREAST05)

for HER2-positive Breast Cancer

Sponsor: First Affiliated Hospital of Zhejiang University

Sex: Female·Age: 18 - 75

Code: NCT06832904·Phase 2

Apply to this trial

Diagnostic HER2DX-guided Treatment for Patients wIth Early-stage HER2-positive Breast Cancer

for HER2-positive Breast Cancer

Sponsor: Fundacio Clinic Barcelona

Sex: All·Age: 18+

Code: NCT06446882

Apply to this trial

T-DXd Versus THP for Medium-risk HER2-positive Early Breast Cancer

for HER2-positive Breast Cancer

Sponsor: Fudan University

Sex: Female·Age: 18+

Code: NCT06548178·Phase 2

Prolonged Overnight Fasting and/or Exercise on Fatigue and Other Patient Reported Outcomes in Women With Hormone Receptor Positive Advanced Breast Cancer

for HER2-positive Breast Cancer

3 sites incl. Phoenix

Sponsor: University of Miami

Sex: Female·Age: 18+

Code: NCT06123988

Apply to this trial

The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer

for Breast Cancer Female

1 site in Boston

Sponsor: Dana-Farber Cancer Institute

Sex: All·Age: 18+

Code: NCT06439693·Phase 2

Apply to this trial

Identification of Risk Factors for Brain Recurrence in Patients With HER2-positive Localised Breast Cancer

for HER2-positive Breast Cancer

Sponsor: Center Eugene Marquis

Sex: Female·Age: 18+

Code: NCT06358625

Apply to this trial

Basket Study for Oligo-metastatic Breast Cancer

for HER2-positive Breast Cancer

Sponsor: The Netherlands Cancer Institute

Sex: All·Age: 18+

Code: NCT05982678·Phase 2

Apply to this trial

Pyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast Cancer

for HER2-positive Breast Cancer

Sponsor: Hebei Medical University Fourth Hospital

Sex: Female·Age: 18 - 65

Code: NCT07635342·Phase 2

Apply to this trial

A Phase 1/1b Study of IAM1363 in HER2 Cancers

for HER2 Mutation-Related Tumors

29 sites incl. La Jolla

Sponsor: Iambic Therapeutics, Inc

Sex: All·Age: 18+

Code: NCT06253871·Phase 1

Apply to this trial

The Resistance Mechanism of Trastuzumab Deruxtexan in HER2 Positive Breast Cancer Patients.

for HER2-positive Breast Cancer

Sponsor: Samsung Medical Center

Sex: Female·Age: All ages·Accepts healthy volunteers

Code: NCT06330012

Apply to this trial

DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer

for HER2-positive Breast Cancer

Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Sex: All·Age: 18+

Code: NCT06313086·Phase 3

Apply to this trial

Clinical Application of ctDNA Dynamic Monitoring in Neoadjuvant Therapy for HER2-positive Breast Cancer Patients

for Breast Cancer

Sponsor: The First Affiliated Hospital with Nanjing Medical University

Sex: Female·Age: 18 - 75

Code: NCT06479460

Apply to this trial

Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer

for Breast Cancer

1 site in Stony Brook

Sponsor: Alison Stopeck

Sex: Female·Age: 18+

Code: NCT06220214·EARLY_Phase 1

Apply to this trial

RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study

for Radiomic

Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Sex: All·Age: All ages

Code: NCT07030569

Apply to this trial

Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast Cancer

for Breast Cancer

Sponsor: Henan Cancer Hospital

Sex: Female·Age: 18 - 70

Code: NCT06276868·Phase 2

Apply to this trial

A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)

for HER2-positive Breast Cancer

Sponsor: Daiichi Sankyo

Sex: All·Age: 18+

Code: NCT06210776

Apply to this trial

The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).

for HER2-positive Breast Cancer

Sponsor: Hebei Medical University Fourth Hospital

Sex: Female·Age: 18 - 70

Code: NCT06217185·Phase 4

Apply to this trial

HER2-positive breast cancer clinical trials — common questions

Are her2-positive breast cancer clinical trials free to join?

Yes. Participating in a her2-positive breast cancer clinical trial is free — study-related visits, tests, and the investigational treatment are provided at no cost to you. Many studies also reimburse travel and time. You never pay to take part.

Who can join a her2-positive breast cancer clinical trial?

Each her2-positive breast cancer study sets its own eligibility criteria — typically based on age, medical history, current treatments, and overall health. Every trial listed here shows its criteria, and the study team confirms your eligibility before enrollment. You can review and apply to any that look like a fit.

How do I find a her2-positive breast cancer trial near me?

Use the location controls above. We'll show recruiting her2-positive breast cancer trials with sites near you, sorted by distance. You can widen the radius or share your exact location for the closest matches.

How many her2-positive breast cancer trials are recruiting right now?

We're currently tracking roughly 30 recruiting her2-positive breast cancer trials with US sites, sourced from ClinicalTrials.gov and refreshed daily.

Looking for a specific location? Browse trials by city and state.

HER2-positive breast cancer trials by city

Boston, MA Birmingham, AL Chicago, IL Indianapolis, IN La Jolla, CA Clearwater, FL Columbus, OH Long Beach, CA Miami, FL San Francisco, CA Tampa, FL

Related specialties

Oncology Breast oncology